Sehydrin pills coated 60mg №50

Packaging

50 pieces

Mechanism of action

SEGIDRIN inhibits the growth of tumor cells. Affects a number of biochemical processes: inhibits MAO, reduces the permeability of cell membranes and cell organelles, inhibits the metabolism of xenobiotics. It has a symptomatic effect on malignant tumors in the later stages.

Indications and usage

Locally common and disseminated forms of malignant neoplasms, incl. in patients with cytopenia caused by Chemotherapy and radiation therapy and with jaundice, especially obturative, caused by metastases to the liver, including advanced stages, including preterminal phase (to improve well-being and mood).

Contraindications

Hypersensitivity.

Dosage and administration

Inside, 1–2 hours before a meal or 1–2 hours after a meal (or taking other drugs) - 1 tab. 3 times a day, with poor tolerance - table 2.per day; course - 100 tab. A repeated course is held at intervals of at least 14 days; the number of courses is not limited, with the intervals between courses increasing by 1–2 weeks.

Adverse reactions

Dyspeptic phenomena, incl. nausea, vomiting, belching (disappear with a dose reduction or a 2-3-day break in treatment), rarely - insomnia, general arousal, transient symptoms of polyneuritis.

Drug interactions

Simultaneous reception with barbiturates leads to the development of toxic effects.

In experiments on laboratory animals, it has been shown that preliminary administration of segidrin increases the effectiveness of many anticancer drugs (an exception is cyclophosphamide).